Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia–results of a phase I dose-escalation study

J.F. DiPersio (1), H.P. Erba (2), R.A. Larson (3), S.M. Luger (4), M.S. Tallman (5), J.M. Brill (6), G. Vuagniaux (7), E. Rouits (7), J.M. Sorensen (6), C. Zanna (7).

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):443-9. doi: 10.1016/j.clml.2015.02.020. Epub 2015 Mar 5.

Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO. Electronic address: jdipersi@dom.wustl.edu
University of Michigan, Ann Arbor, MI.
University of Chicago Medicine, Chicago, IL.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Memorial Sloan Kettering Cancer Center, New York, NY.
Ascenta Therapeutics Inc, Malvern, PA.
Debiopharm International S.A., Lausanne, Switzerland.